pSivida Limited (PSDV) Says RetisertTM Drug Implant Receives Product Specific Bill Code and Medicare Reimbursement Rate
More News related to BOL
- Fred Hassan Joins Bausch & Lomb Board of Directors
- Bausch & Lomb Unveils FogShield Sport(TM), an Anti-Fog Treatment for Sports Goggles That Works
- Boliden: Interim Report, January - September 2009
- Center for Patient Insights Web Site Goes Live
- Pierre Heeroma - New Director Group Strategy and Business Development at Boliden
More News related to PSDV
- pSividia (PSDV) Files $42M Mixed Shelf
- pSivida (PSDV) Files $41.99M Mixed Securities Shelf
- Ladenburg Thalmann Initiates Coverage on pSivida (PSDV) with a Buy
- pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009
- Trading Radar for 11/12: Wal-Mart (WMT), Blockbuster (BBI), Nordstrom (JWN), Walt Disney (DIS), Kohl's (KSS) Report
More News related to Corporate News
- Peregrine Pharma (PPMD) Completes Enrollment for Dosimetry Trial of Brain Cancer Drug Cotara
- CoStar Group (CSGP) and LoopNet Settle All Litigation
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- Wells Fargo (WFC) To Close 122 Branches in California
- AMETEK (AME) Acquires Pressurized Gas Systems Business of Ameron Global
pSivida Limited (NASDAQ: PSDV) announced that Retisert, developed jointly by pSivida and Bausch & Lomb (NYSE: BOL), has been allocated a product specific J-Code by the Centers for Medicare and Medicaid Services (CMS) in the United States.
The RetisertTM implant was approved as a single indication orphan drug by the United States Food and Drug Administration for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening inflammatory disease and a major cause of blindness. RetisertTM is surgically placed into the back of the eye and releases the steroid, fluocinolone acetonide at a constant rate over a period of up to 30 months. Marketed in the United States by Bausch & Lomb, pSivida receives royalties on sales.
Related Categories
Corporate NewsStocks Mentioned
+0.00
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
